Objective: High-dose therapy (HDT) for small-cell lung cancer is experimental. Late intensification HDT for chemosensitive disease can increase the number and quality of remissions and prolong relapse-free survival, but has not yet shown impact on overall survival. This is possibly due to resistant residual disease. To overcome the development of resistance, we have tested early intensification tandem HDT. Methods: We performed a phase-I/II trial using 1 conventional cycle of ifosfamide, carboplatin, etoposide (ICE) plus granulocyte colony-stimulating factor for stem cell recruitment followed by 2 cycles of high-dose ICE with rescue by CD34+ cell-enriched peripheral blood mononuclear cells. Dose escalation was performed for the 2 high-dose ICE cycles. Radiotherapy for limited disease was according to standard protocols. Results: 17 patients were entered: 2 female patients; 15 male patients; median age 53 (range 36–65) years; 2 patients with limited disease, and 15 patients with extensive disease. We treated 4 patients at dose level 1, 11 patients at level 2, and 2 patients at level 3. The maximum tolerable dose was at level 2 with neuropathy being dose-limiting. Overall, toxicity was ≤grade 2 for all patients up to dose level 2 with hematotoxicity being grade 4 for all patients. There were 15 partial remissions (88%), 1 no change (6%), and 1 progressive disease (6%). Median time to progression was 7.9 months. Overall survival was 12.9 months (median). Conclusions: Early intensification with this protocol is feasible. Although a comparatively good response rate and median time to progression have been observed in this group dominated by patients with extensive disease, overall survival is short and no substantial long-term survival was found.

Keywords:
Small-cell lung cancer, Tandem high-dose therapy, Stem cell rescue
1.
Smyth JF, Fowlie SM, Gregor A, Crompton GK, Busuttil A, Leonard RC, Grant IW: The impact of chemotherapy on small cell carcinoma of the bronchus. Q J Med 1986;61:969–976.
2.
Clark R, Ihde DC: Small-cell lung cancer: Treatment progress and prospects. Oncology (Huntingt.) 1998;12:647–658.
3.
Sandler AB: Current management of small cell lung cancer. Semin Oncol 1997;24:463–476.
4.
Elias A: Dose-intensive therapy in lung cancer. Cancer Chemother Pharmacol 1997;40(suppl):64–69.
5.
Hanauske AR, Korfel A, Perker M, Heinrich B, Schwab G, Graf M, Depenbrock H, Höffken G, Kreuser E-D, Thiel E, Zwingers T, Berdel WE: Dose intensity phase I/II trial with carboplatin, ifosfamide, etoposide and vincristine combined with filgrastim in patients with small-cell lung cancer. Oncology 1997;54:363–370.
6.
Thatcher N, Girling DJ, Hopwood P, Sambrook RJ, Qian W, Stephens RJ, for the Medical Research Council Lung Cancer Working Party: Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: Results of a British Medical Research Council multicenter randomized trial. J Clin Oncol 2000;18:395–404.
7.
Steward WP, von Pawel J, Gatzemeier U, Woll P, Thatcher N, Koschel G, Clancy L, Verweij J, de Wit R, Pfeifer W, Fennelly J, von Eiff M, Frisch J: Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: A prospective randomized study of 300 patients. J Clin Oncol 1998;16:642–650.
8.
Pujol J-L, Douillard J-Y, Riviere A, Quoix E, Lagrange J-L, Berthaud P, Bardonnet-Comte M, Polin V, Gautier V, Milleron B, Chomy F, Chomy P, Spaeth D, Le Chevalier T: Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: A multicenter randomized phase III study. J Clin Oncol 1997;15:2082–2089.
9.
Trillet-Lenoir V, Green JA, Manegold C, von Pawel J, Gatzemeier U, Lebau B, Depierre A, Johnson P, Decoster G, Matcham J, Ewen C: Recombinant granulocyte colony stimulating factor in the treatment of small cell lung cancer: A long-term follow-up. Eur J Cancer 1995;31A:2115–2116.
10.
Bunn PA, Crowley J, Kelly K, Hazuka MB, Beasley K, Upchurch C, Livingston R: Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: A prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol 1995;13:1632–1641.
11.
Elias AE, Cohen BF: Dose-intensive therapy in lung cancer; in Armitage JO, Antman KH (eds): High-Dose Cancer Therapy, ed 2. Baltimore, Williams & Wilkins, 1995, pp 824–846.
12.
Humblet Y, Symann M, Bosly A, Delaunois L, Francis C, Machiels J, Beauduin M, Doyen C, Weynants P, Longueville J, Prignot J: Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: A randomized study. J Clin Oncol 1987;5:1864–1873.
13.
Arriagada R, Le Chevalier T, Pignon J-P, Riviere A, Monnet I, Chomy P, Tuchais C, Tarayre M, Ruffie P: Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med 1993;329:1848–1852.
14.
Hornung RL, Longo DL: Hematopoietic stem cell depletion by restorative growth factor regimens during repeated high-dose cyclophosphamide therapy. Blood 1992;80:77–83.
15.
Leyvraz S, Perey L, Rosti G, Lange A, Pampallona S, Peters R, Humblet Y, Bosquée L, Pasini F, Marangolo M: Multiple courses of high-dose ifosfamide, carboplatin, and etoposide with peripheral-blood progenitor cells and filgrastim for small-cell lung cancer: A feasibility study by the European Group for Blood and Marrow Transplantation. J Clin Oncol 1999;17:3531–3539.
16.
Pettengell R, Woll PJ, Thatcher N, Dexter TM, Testa NG: Multicyclic, dose-intensive chemotherapy supported by sequential reinfusion of hematopoietic progenitors in whole blood. J Clin Oncol 1995;13:148–156.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.